# An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia

> **NCT01245530** · PHASE3 · COMPLETED · sponsor: **Whanin Pharmaceutical Company** · enrollment: 280 (actual)

## Conditions studied

- Alzheimer Type Dementia

## Interventions

- **DRUG:** Aricept
- **DRUG:** INM-176

## Key facts

- **NCT ID:** NCT01245530
- **Lead sponsor:** Whanin Pharmaceutical Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2011-02
- **Final completion:** 2011-03
- **Target enrollment:** 280 (ACTUAL)
- **Last updated:** 2011-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01245530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01245530, "An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01245530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*